|
BrainStorm Announces Clinical Data Supporting Safety, Efficacy of NurOwn
BrainStorm Cell Therapeutics announced that the data from the initial patients in its ALS Phase I/II human clinical trial treated with its NurOwn technology did not present any significant side effects and that the NurOwn treatment has so far proven to be safe.
The Street |
Register Now
Archives